Related Experiment Video

Updated: Mar 7, 2026

A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro
10:36

A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro

Published on: January 9, 2018

7.6K

Novel TGF-β inhibitors ready for prime time in onco-immunology

Armand de Gramont1, Sandrine Faivre2, Eric Raymond3

  • 1AFR Oncology, Boulogne-Billancourt , France.

Oncoimmunology
|February 16, 2017
PubMed

Insights

Transforming Growth Factor (TGF)-β inhibitors show promise as effective cancer treatments. Recent clinical data suggest these drugs are moving from theoretical candidates to viable therapeutic options.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Transforming Growth Factor (TGF)-β signaling plays a crucial role in cancer progression.
  • Targeting TGF-β has been a long-standing strategy in cancer therapy development.

Purpose of the Study:

  • To evaluate the clinical efficacy of TGF-β inhibitors.
  • To assess the transition of TGF-β inhibitors from promising candidates to effective drugs.

Main Methods:

  • Review of clinical trial data presented at the 2016 ASCO meeting.
  • Analysis of converging evidence from recent studies.

Main Results:

  • Recent clinical results indicate significant therapeutic potential.
  • Evidence suggests TGF-β inhibitors are now effective drug nominees.

Conclusions:

  • TGF-β inhibitors represent a significant advancement in cancer treatment.
  • The drug development pipeline for TGF-β inhibitors has reached a new phase of efficacy.
Keywords:
Belagenpumatucel-LXOMA089clinical trialsfresolimumabgalunisertibgemogenovatucel-Ttrabedersen

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.6K
Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System11:06

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System

Published on: July 30, 2018

11.1K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.8K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
618
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
672
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K